Replies to post #83087 on Amarantus Bioscience Holdings Inc (AMBS)

[jembers]

Curious who his sources are that say BD confirms the test to be negative.

[LoveAndLight]

Honestly, do you expect anyone to believe this poster's claims with all the trading agenda that is going on right now? Ulterior motives by a trading group trying to drive the price down lower? Obviously this is clearly the case. First off, they wouldn't have secured funding had there been any "negative" results. I would suggest you rely exclusively upon what the company has been reporting, which has been nothing but "positive" data, and not what some anonymous poster comments on a website or message board. Good luck!

Best wishes,
LoveAndLight :-)

[blackhawks]

Any opinions/answers to these questions? Just curious:

According to my sources, BD LymPro results have come out of negative. They will not be receiving any funding from BD for CLIA. That is the reason why AMBS had to raise $3M immediately.

"My sources", despite claims made for a similarly described entitiy by some posters on this board, are unverifiable and should be taken with a grain.

The need for funding has been noted by AMBS for some time now and the 'souces' claim seems to be contradicted by the statement below released today.

Any communication from BD to AMBS about failure of the LymPro assays being done by by BD would likely result in the omission of any mention of commercialization in today's PR from AMBS.

this transaction will allow the Company to operate well into 2014, where we expect to begin generating revenue through LymPro commercialization and bring MANF closer to first-in-man human clinical studies."

Could it be that AMBS is a scam?

Comes at the end of a paragraph noting the impressive presence of the impressively credentialed Dr. Rubinfeld. Nuff said.

Some of the recent peer-reviewed publications are coming from independent groups working on MANF. How does their success (for whatever indications they are researching on) help AMBS?

Any independent research pointing to the usefullness of MANF shows up on the radar screens of Pharm companies looking for such results from compounds in their earliest stages of development.

That is organic news for AMBS that costs nothing and which places the MANF story in front of potential collaborators/JV partners.

[blackhawks]

Also, according to MY sources, Gerald shares the same impatience for hearing bad news as soon as possible as did Vito Corleone:

Tom Hagen: Thank you for the dinner and a very pleasant evening. Have your car take me to the airport. Mr Corleone is a man who insists on hearing bad news at once.

So I don't think that alleged 'bad results' for LymPro would fail to be delivered in time to alter today's PR.